Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Pharmatech Returns To TPG Fold
by Lisa M. Jarvis
February 23, 2015
| A version of this story appeared in
Volume 93, Issue 8
Actavis is selling its drug manufacturing and R&D unit Aptalis Pharmaceutical Technologies, also known as Pharmatech, to the private investment firm TPG. Aptalis came into the Actavis fold through its $25 billion acquisition of Forest Laboratories, which had bought Aptalis from TPG in January 2014. The sale, for an undisclosed sum, comes as Actavis plans for an expanded manufacturing network stemming from its pending $66 billion acquisition of Allergan. Other parts of Aptalis remain with Actavis.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X